Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 10 of 10 for “"Biotech companies"”.
-
Uusing the KDJ as a trading strategy on biotech companies
… build a new model involved with the KDJ. Taking biotech companies marketed in the United States and B-share marketed in China as the research subjects, the result shows increased profits compared with the Mean Reversion model. It also shows that as long as we clearly understand the relationship …
-
A New Campus in the City: Place-Making in South Lake Union
… innovation and thriving campus for high-tech and biotech companies. In this project, I explore the place-making practices of the professionals who commute to South Lake Union to work for these global corporations. My focus on their day-to-day activities in public space and on their discourses …
-
THIS IS YOUR BRAIN ON DRUGS: A MULTIMODAL NEUROIMAGING AND COMPUTATIONAL INVESTIGATION INTO THE EFFECTS OF PSYCHEDELIC TRYPTAMINES AND MDMA ON HUMAN BRAIN DYNAMICS
… by the FDA. With nearly 100 pharmaceutical and biotech companies developing novel therapeutics from these compounds, it is essential to understand their mechanisms and impacts on the human brain. In this dissertation, we first explore the acute effects of psychedelic drugs on human brain …
-
The evaluation of system-wide financial incentives in pipeline decisions in the pharmaceutical and biotechnology industry : the paradox of R&D spend Vs. new drug approvals
… several decades, the ascendancy of the Pharma & Biotech sector was largely driven by favorable macro-economic conditions combined with an astonishing level of innovation and a clear focus on addressing unmet medical needs. Significant R&D investments led to innovative drugs that changed clinical …
-
The U.S. Print Media's Framing of the Genetic Modification of Food
… parts of the world, consumer opposition to this biotechnology has been modest in the U.S., and numerous studies have found that most Americans are unconcerned about this paradigm shift in agriculture. Although the genetic modification (GM) literature is substantial, little research has examined …
-
Improving the efficiency of the later stages of the drug development process : survey results from the industry, academia, and the FDA
… fee payments to the FDA by the drug developing companies. Data on approval times for new drugs indicate that this process was indeed shortened. In contrast, the average drug development process prior to the filing of an application has been increasing in cost and time. The first purpose of this …
-
Financing the "Valley of Death" : an evaluation of incentive schemes for global health businesses
Many early-stage biotech companies face a significant funding gap when trying to develop a new drug from preclinical development to a proof of concept clinical trial. This funding gap is sometimes referred to as the "valley of death", a reflection of the vast number of companies that are unable to …
-
Critical Mass of Women on Biotech Corporate Boards and Its Implication For Firm Performance: A Mixed Method Explanatory Sequential Study
… on firm performance of North American Biotech companies using a mixed method explanatory sequential approach. One-year cross-sectional data of 100 companies was analyzed followed by purposeful semistructured interviews with eight board members from the dataset. The combined results …
-
Leveraging Local Perturbations to Map Allosteric Networks of Phosphatases
… docking simulations. I also worked with biotech companies who applied their technologies to a SBDD approach to design potential allosteric modulators. We uncovered both allosteric inhibitors and benign binders, and I determined the crystal structure of a designed compound bound to the …
-
Engineering mammalian cell line to improve sialylation
One of the key problems faced by many biotechnology companies is the cleavage of terminal sialic acid on the glycans of the therapeutic glycoproteins. This is caused by the degradative action of sialidase released to supernatant when the cell starts to die. This phenomenon is undesirable because …